Cite
HARVARD Citation
Bonnefoi, H. et al. (n.d.). 368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306). Annals of oncology. p. . [Online].